Michele Moschetta, Marta Cesca, Francesca Pretto and Raffaella Giavazzi Pages 3921 - 3931 ( 11 )
Angiogenesis is associated with tumor development and malignancy and is a validated target for cancer treatment. Preclinical and clinical evidence substantiates the feasibility of combining angiogenesis inhibitors with conventional anticancer therapy. This review discusses recent progress in combining antiangiogenic drugs, mainly acting on the VEGF/VEGFR pathway, with chemotherapy and other conventional therapies. Strategies for the optimization of combination therapy and the selection of appropriate treatment regimens are examined. As new drugs are entering clinical trials, reliable biomarkers are needed to stratify patients for antiangiogenic therapy, to identify resistant patients and to monitor response to treatment.
Angiogenesis,VEGF,Combination Therapy,Biomarker,Resistance,Toxicity,bevacizumab,Avastin,TKRI,sunitinib,GIST,pazopanib,EGFR,PDGFR,FGFR,CRC,NSCLC,ABT-869,Axitinib,BIBF1120,Brivanib,Cediranib,Dovitinib,Foretinib,Motesanib,Sorafenib,Vandetanib,Vatalanib,ZD6474,carboplatin,paclitaxel,trastuzumab,Radio-Immunotherapy,Tregs,TKRI therapy,PlGF,hypothyroidism,neuropathy
, , , Department of Oncology, Mario Negri Institute for Pharmacological Research, Via La Masa, 19; 20156 Milan, Italy.